. Wang HY, Wang RF. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res 2016;27:11–37.
. Esfandiary A, Ghafouri-Fard S. New York esophageal squamous cell carcinoma-1 and cancer immunotherapy. Immunotherapy 2015;7:411–39.
. Grizzi F, Mirandola L, Qehajaj D, et al. Cancer-testis antigens and immunotherapy in the light of cancer complexity. Int Rev Immunol 2015;34:143–53.
. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004;101:10697–702.
. Nicholaou T, Ebert LM, Davis ID, et al. Regulatory T-cell mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res 2009;15:2166–73.
. Aoki M, Ueda S, Nishikawa H, et al. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)- NY-ESO-1 and CHP-HER2 with OK-432. Vaccine 2009;27:6854–61.
. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival
endpoints. Stat Med 1998;17:2815–34.
. Williamson PR, Smith CT, Hutton JL, et al. Aggregate data meta-analysis
with time-to-event outcomes. Stat Med 2002;21:3337–51.
. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis
. Trials 2007;8:16.
. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
. Szender JB, Papanicolau-Sengos A, Eng KH, et al. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecol Oncol 2017;145:420–5.
. Mori M, Funakoshi T, Kameyama K, et al. Lack of XAGE-1b and NY-ESO-1 in metastatic lymph nodes may predict the potential survival
of stage III melanoma patients. J Dermatol 2017;44:671–80.
. Veit J, Heine D, Thierauf J, et al. Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. Head Neck 2016;38:1008–16.
. Lee HJ, Kim JY, Song IH, et al. Expression of NY-ESO-1 in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and a good prognosis. Oncology 2015;89:337–44.
. Grah JJ, Katalinic D, Juretic A, et al. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer. Tumori 2014;100:60–8.
. Laban S, Atanackovic D, Luetkens T, et al. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival
in head and neck cancer. Int J Cancer 2014;135:1142–52.
. Gjerstorff MF, Pøhl M, Olsen KE, et al. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma. BMC Cancer 2013;13:466.
. John T, Starmans MH, Chen YT, et al. The role of cancer-testis antigens as predictive and prognostic markers in non-small cell lung cancer. PLoS One 2013;8:e67876.
. Liang J, Ding T, Guo ZW, et al. Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. Br J Cancer 2013;109:1031–9.
. Balafoutas D, Zur Hausen A, Mayer S, et al. Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications. BMC Cancer 2013;13:271.
. Ademuyiwa FO, Bshara W, Attwood K, et al. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS One 2012;7:e38783.
. Dyrskjøt L, Zieger K, Lildal TK, et al. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br J Cancer 2012;107:116–22.
. Zhou JX, Li Y, Chen SX, et al. Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma. J Exp Clin Cancer Res 2011;30:2.
. Pastorcic-Grgic M, Sarcevic B, Dosen D, et al. Prognostic value of MAGE-A and NY-ESO-1 expression in pharyngeal cancer. Head Neck 2010;32:1178–84.
. Kim SH, Lee S, Lee CH, et al. Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung 2009;187:401–11.
. Napoletano C, Bellati F, Tarquini E, et al. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol 2008;198: 99.e1-7.
. Bellati F, Napoletano C, Tarquini E, et al. Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors. Eur J Cancer 2007;43:2621–7.
. Velazquez EF, Jungbluth AA, Yancovitz M, et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)—correlation with prognostic factors. Cancer Immun 2007;7:11.
. Yakirevich E, Sabo E, Lavie O, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 2003;9:6453–60.
. Gure AO, Chua R, Williamson B, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non small cell lung cancer. Clin Cancer Res 2005;11:8055–62.
. Akcakanat A, Kanda T, Tanabe T, et al. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: implications for immunotherapy. Int J Cancer 2006;118:123–8.
. Fujita S, Wada H, Jungbluth AA, et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 2004;10:6551–8.
. Iura K, Maekawa A, Kohashi K, et al. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum Pathol 2016;61:130–9.
. Rodolfo M, Luksch R, Stockert E, et al. Antigen-specific immunity in neuroblastoma patients antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 2003;63:6948–55.
. Nicholaou T, Eber L, Davis ID, et al. Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol 2006;84:303–17.
. Cho H, Caballero OL, Gnjatic S, et al. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immun 2006;6:12.
. Hayes SJ, Hng KN, Clark P, et al. Immunohistochemical assessment of NYESO-1 expression in esophageal adenocarcinoma resection specimens. World J Gastroenterol 2014;20:4011–6.
. Cronwright G, Le Blanc K, Gotherstrom C, et al. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 2005;65:2207–15.
. Yawata T, Nakai E, Park KC, et al. Enhanced expression of cancer testis antigen genes in glioma stem cells. Mol Carcinog 2010;49:532–44.